vimarsana.com

Latest Breaking News On - பராமரிப்பு சிகிச்சை - Page 5 : vimarsana.com

Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission

If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia (AML) subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission

Announcing India s first clinically tested medicine for COVID-19 management and treatment AAYUDH Advance

Ahmedabad (Gujarat) [India], April 16 (ANI/NewsVoir): With the second wave of COVID-19 pandemic wreaking havoc across the world, a breakthrough has been achieved to provide effective medical care and a treatment for COVID-19 patients. AAYUDH Advance , a plant-based liquid formulation, has been found to be highly effective and safe in not one but two detailed human clinical trials conducted at two government hospitals in Ahmedabad. After just four days of treatment with AAYUDH Advance , it successfully and effectively reduced the viral load in the patients, without any reported side effects. All the COVID-19 patients that were treated with AAYUDH Advance recovered (i.e. turned COVID Negative) and witnessed significant improvements in symptoms like body temperature, cough, and shortness of breath.

New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ in Psoriatic Arthritis

ABBVie today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs . 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 … ABBVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week 12 versus placebo as well as key secondary endpo

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.